VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Ocular Therapeutix, Inc. (OCUL) Total Return Calculator with Dividends Reinvested

Ocular Therapeutix, Inc.

Popular:

The total return for Ocular Therapeutix, Inc. (OCUL) stock is +35.24% over the past 12 months. So far it's down 17.85% this year. The 5-year total return is -38.82%, meaning $10,000 invested in OCUL stock 5 years ago would be worth $6,118 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in OCUL 1 year ago, it would be worth $13,773 today — you'd have gained $3,773.

With Dividends Reinvested$13,773+37.73%

Price Only (No DRIP)$13,773+37.73%

Period2025-05-07 → 2026-05-06

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in OCUL

1Y$13,524+$3,524 (+35.2%)35.2% CAGR

3Y$15,172+$5,172 (+51.7%)14.9% CAGR

5Y$6,118-$3,882 (-38.8%)-9.4% CAGR

10Y$9,557-$443 (-4.4%)-0.5% CAGR

15Y$7,384-$2,616 (-26.2%)-2.0% CAGR

20Y$7,384-$2,616 (-26.2%)-1.5% CAGR

30Y$7,384-$2,616 (-26.2%)-1.0% CAGR

Ocular Therapeutix, Inc. did not pay dividends during this period. Total return = price return.

Loading OCUL total return...

As of 2026-05-07

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-17.85%	—	-17.85%	—	$8,215
1Y	+35.24%	35.24%	+35.24%	—	$13,524
3Y	+51.72%	14.91%	+51.72%	—	$15,172
5Y	-38.82%	-9.36%	-38.82%	—	$6,118
10Y	-4.43%	-0.45%	-4.43%	—	$9,557
15Y	-26.16%	-2.00%	-26.16%	—	$7,384
20Y	-26.16%	-1.50%	-26.16%	—	$7,384
30Y	-26.16%	-1.01%	-26.16%	—	$7,384

Risk & Highlights

Best Year+424.05%2020

Worst Year-65.03%2021

Max Drawdown-57.32%2025-12-08 → 2026-02-17

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-24.37%	-24.37%	—	+0.41%	-24.8pp
2025	+38.90%	+38.90%	—	+16.64%	+22.3pp
2024	+77.55%	+77.55%	—	+24.00%	+53.5pp
2023	+59.86%	+59.86%	—	+24.81%	+35.0pp
2022	-61.77%	-61.77%	—	-19.95%	-41.8pp

OCUL outperformed the S&P 500 by 3.91pp over the past year (+35.24% vs +31.32%).

Loading summary...

OCUL Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
OCULOcular Therapeutix, Inc.	$2.1B	+20.3%	-17.9%	+35.2%	—	+51.7%	-38.8%	-4.4%
RCKTRocket Pharmaceuticals, Inc.	$418M	+11.6%	+11.6%	-38.8%	—	-81.9%	-91.1%	-90.7%
KALAKALA BIO, Inc.	$855,530	-33.4%	-81.5%	-96.7%	—	-99.3%	-100.0%	-100.0%
ALDXAldeyra Therapeutics, Inc.	$105M	+14.5%	-62.7%	-17.1%	—	-83.7%	-85.6%	-71.9%
NVCRNovoCure Limited	$1.9B	+56.4%	+25.7%	+1.0%	—	-76.2%	-91.5%	+31.0%
SGHTSight Sciences, Inc.	$232M	+21.1%	-42.5%	+53.0%	—	-59.1%	-87.2%	-87.2%
LNTHLantheus Holdings, Inc.	$5.6B	+13.5%	+28.1%	-17.8%	—	-9.1%	+290.0%	+4002.4%
RXSTRxSight, Inc.	$280M	-3.4%	-34.7%	-51.4%	—	-65.1%	-57.6%	-57.6%
ATRCAtriCure, Inc.	$1.4B	-4.0%	-28.7%	-6.2%	—	-41.4%	-64.0%	+100.6%
NVAXNovavax, Inc.	$1.5B	+17.4%	+31.3%	+54.2%	—	+25.6%	-94.6%	-89.8%
PRPHProPhase Labs, Inc.	$6M	+69.9%	-61.1%	-48.2%	—	-96.7%	-62.9%	+38.3%

Compare:OCUL vs RCKT OCUL vs KALA OCUL vs ALDX OCUL vs RCKT vs KALA

About OCUL Dividend Returns

Ocular Therapeutix, Inc. (OCUL) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of OCUL over the past year?

Ocular Therapeutix, Inc. (OCUL) delivered a return of 35.24% over the past year. Since OCUL does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in OCUL be worth today?

A $10,000 investment in Ocular Therapeutix, Inc. one year ago would be worth $13,524 today, representing a gain of $3,524.

Q3Does OCUL pay dividends?

Ocular Therapeutix, Inc. (OCUL) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For OCUL, the total return equals the price-only return.

Q4Did OCUL beat the S&P 500?

Yes, Ocular Therapeutix, Inc. (OCUL) outperformed the S&P 500 by 3.91 percentage points over the past year. OCUL delivered a total return of 35.24%, compared to the S&P 500's 31.32%. This 3.91pp alpha means investors in OCUL earned more than a passive S&P 500 index fund.

Q5What is OCUL's worst drawdown?

Ocular Therapeutix, Inc. (OCUL) experienced a maximum drawdown of -57.32% over the past year, declining from its peak on 2025-12-08 to its trough on 2026-02-17. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is OCUL's long-term total return over 10, 20, or 30 years?

Here are Ocular Therapeutix, Inc. (OCUL)'s long-term returns with dividends reinvested. Over 10 years, the total return is -4.4% (-0.5% CAGR) — $10,000 would have grown to $9,557. Over 20 years: -26.2% total return (-1.5% CAGR) — $10,000 → $7,384. Over 30 years: -26.2% total return (-1.0% CAGR) — $10,000 → $7,384. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was OCUL's best and worst year?

Ocular Therapeutix, Inc.'s best calendar year was 2020 with a total return of 424.1%. Its worst year was 2021 with a total return of -65.0%. This range shows the volatility investors should expect — the difference between the best and worst year is 489.1 percentage points.